Active Ingredient History
Leucovorin is a compound similar to folic acid, which is a necessary vitamin. It has been around and in use for many decades. Leucovorin is a medication frequently used in combination with the chemotherapy drugs fluoruracil and methotrexate. Leucovorin is not a chemotherapy drug itself, however it is used in addition to these chemotherapy drugs to enhance anticancer effects (with fluorouracil) or to help prevent or lessen side effects (with methotrexate). Leucovorin is also used by itself to treat certain anemia problems when folic acid deficiency is present. NCATS
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Anemia, Megaloblastic (approved 1953)
Colorectal Neoplasms (approved 1953)
Osteosarcoma (approved 1953)
Acquired Immunodeficiency Syndrome (Phase 4)
Adenocarcinoma (Phase 3)
Adenoma, Islet Cell (Phase 2/Phase 3)
Anemia (Phase 1)
Antibody-Dependent Cell Cytotoxicity (Phase 2)
Antimetabolites (Phase 2)
Antineoplastic Agents (Phase 3)
Anus Neoplasms (Phase 1)
Appendiceal Neoplasms (Phase 2)
Appendix (Phase 2)
Arthritis, Experimental (Phase 2)
Arthritis, Psoriatic (Phase 1)
Arthritis, Rheumatoid (Phase 2)
Ascorbic Acid (Phase 3)
Asperger Syndrome (Phase 2)
Astrocytoma (Phase 1)
Autism Spectrum Disorder (Phase 3)
Autistic Disorder (Phase 2)
Bevacizumab (Phase 1/Phase 2)
Bile Duct Neoplasms (Phase 2/Phase 3)
Biliary Tract Diseases (Phase 2)
Biliary Tract Neoplasms (Phase 3)
Brain Neoplasms (Phase 3)
Breast Neoplasms (Phase 3)
Burkitt Lymphoma (Phase 2)
Capecitabine (Phase 2)
Carcinoid Tumor (Phase 2)
Carcinoma (Phase 3)
Carcinoma, Basal Cell (Phase 2)
Carcinoma, Hepatocellular (Phase 3)
Carcinoma, Islet Cell (Phase 2)
Carcinoma, Neuroendocrine (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 4)
Carcinoma, Ovarian Epithelial (Phase 1)
Carcinoma, Pancreatic Ductal (Phase 2)
Carcinoma, Renal Cell (Phase 1/Phase 2)
Carcinoma, Squamous Cell (Phase 2)
Carcinoma, Transitional Cell (Phase 2)
Cardiotoxicity (Phase 3)
Cetuximab (Phase 2)
Chemotherapy, Adjuvant (Phase 3)
Child Development Disorders, Pervasive (Phase 2)
Cholangiocarcinoma (Phase 4)
Chondrosarcoma (Phase 1)
Choriocarcinoma (Phase 3)
Choroid Plexus Neoplasms (Phase 3)
Chromosome Aberrations (Phase 2)
Circulating Tumor DNA (Phase 2)
Cognition Disorders (Phase 3)
Colonic Diseases (Phase 2)
Colonic Neoplasms (Phase 4)
Colorectal Neoplasms (Phase 4)
Coronavirus (Phase 1/Phase 2)
COVID-19 (Phase 1/Phase 2)
Cytokine-Induced Killer Cells (Phase 4)
Depression (Phase 3)
Dermatology (Phase 2)
Diabetic Foot (Phase 2)
Diarrhea (Phase 2)
Digestive System Neoplasms (Phase 3)
DNA, Mitochondrial (Phase 1)
DNA Repair-Deficiency Disorders (Phase 3)
Docetaxel (Phase 2/Phase 3)
Down Syndrome (Phase 3)
Drugs, Investigational (Phase 3)
Drug Therapy (Phase 3)
Encephalitis (Phase 4)
Endometrial Neoplasms (Phase 2)
Esophageal Diseases (Phase 3)
Esophageal Neoplasms (Phase 4)
Esophageal Squamous Cell Carcinoma (Phase 3)
Esophagogastric Junction (Phase 3)
Exanthema (Phase 2)
Fallopian Tube Neoplasms (Phase 2)
Fever (Phase 3)
Fluorouracil (Phase 2/Phase 3)
Gallbladder Neoplasms (Phase 3)
Gangliosidoses, GM2 (Phase 1/Phase 2)
Gastrointestinal Neoplasms (Phase 3)
Gastrointestinal Stromal Tumors (Phase 1)
General Surgery (Phase 3)
Genes, erbB-2 (Phase 2)
Geriatrics (Phase 3)
Germinoma (Phase 1)
Gestational Trophoblastic Disease (Phase 3)
Glioblastoma (Phase 1/Phase 2)
Glioma (Phase 1)
Gliosarcoma (Phase 1)
Graft vs Host Disease (Phase 2/Phase 3)
Hamartoma (Phase 3)
Head and Neck Neoplasms (Phase 3)
Healthy Volunteers (Phase 1)
Hematologic Diseases (Phase 3)
Hematopoietic Stem Cell Transplantation (Phase 2/Phase 3)
Hepatitis C (Phase 3)
Histiocytosis, Langerhans-Cell (Phase 2)
HIV (Phase 4)
HIV Infections (Phase 3)
Hodgkin Disease (Phase 2)
Homocysteine (Phase 1)
Hospital Costs (Phase 3)
Hydatidiform Mole (Phase 3)
Immunotherapy (Phase 2)
Inflammation (Phase 1/Phase 2)
Intestinal Diseases (Phase 2)
Intestinal Neoplasms (Phase 3)
Irinotecan (Phase 2/Phase 3)
Klatskin Tumor (Phase 2)
Length of Stay (Phase 3)
Leukemia (Phase 3)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 3)
Leukemia-Lymphoma, Adult T-Cell (Phase 2)
Leukemia, Myeloid, Acute (Phase 1/Phase 2)
Leukemia, Myeloid, Chronic-Phase (Phase 2)
Leukemia, Myelomonocytic, Chronic (Phase 1/Phase 2)
Liver Diseases (Phase 2)
Liver Neoplasms (Phase 4)
Liver Transplantation (Phase 3)
Lung Neoplasms (Phase 2/Phase 3)
Lupus Erythematosus, Systemic (Phase 1)
Lymphoma (Phase 3)
Lymphoma, AIDS-Related (Phase 2)
Lymphoma, B-Cell (Phase 2/Phase 3)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 3)
Lymphoma, Mantle-Cell (Phase 2)
Lymphoma, Non-Hodgkin (Phase 3)
Lymphoma, T-Cell (Phase 2)
Lymphoproliferative Disorders (Phase 2)
Medulloblastoma (Phase 3)
Melanoma (Phase 1/Phase 2)
Mesothelioma (Phase 4)
Microsatellite Instability (Phase 2)
Mucositis (Phase 2/Phase 3)
Multiple Myeloma (Phase 2)
Mutation (Phase 1/Phase 2)
Myelodysplastic Syndromes (Phase 2)
Myeloproliferative Disorders (Phase 2)
Nasopharyngeal Carcinoma (Phase 3)
Nausea (Phase 2)
Neoadjuvant Therapy (Phase 2)
Neoplasm Metastasis (Phase 4)
Neoplasm Recurrence, Local (Phase 3)
Neoplasms (Phase 3)
Neoplasms, Germ Cell and Embryonal (Phase 3)
Neoplasms, Second Primary (Phase 3)
Neoplastic Cells, Circulating (Phase 3)
Neoplastic Syndromes, Hereditary (Phase 2/Phase 3)
Neuroblastoma (Phase 2)
Neuroectodermal Tumors (Phase 3)
Neuroendocrine Tumors (Phase 4)
Neutropenia (Phase 3)
Oligodendroglioma (Phase 1)
Osteosarcoma (Phase 2)
Ovarian Neoplasms (Phase 2)
Oxaliplatin (Phase 2/Phase 3)
Pain (Phase 1/Phase 2)
Pancreatic Neoplasms (Phase 3)
Peripheral Nervous System Diseases (Phase 2/Phase 3)
Peritoneal Neoplasms (Phase 2/Phase 3)
Pharmacokinetics (Phase 2)
Plasmacytoma (Phase 2)
Pneumonia, Pneumocystis (Phase 3)
Postoperative Complications (Phase 4)
Precancerous Conditions (Phase 1)
Pregnancy, Ectopic (Phase 4)
Primary Myelofibrosis (Phase 1)
Progression-Free Survival (Phase 2)
Prostatic Neoplasms (Phase 1)
Proto-Oncogene Proteins B-raf (Phase 2)
Proto-Oncogene Proteins p21(ras) (Phase 1/Phase 2)
Psychotic Disorders (Phase 3)
Quality of Life (Phase 3)
Radiation (Phase 3)
Radiotherapy (Phase 2/Phase 3)
ras Proteins (Phase 3)
Rectal Neoplasms (Phase 4)
Recurrence (Phase 3)
Retinoblastoma (Phase 2)
Rhabdoid Tumor (Phase 3)
Sandhoff Disease (Phase 1/Phase 2)
Sarcoma (Phase 2)
Schizophrenia (Phase 3)
Seminoma (Phase 2)
Sepsis (Phase 3)
Small Cell Lung Carcinoma (Phase 1)
Squamous Cell Carcinoma of Head and Neck (Phase 1/Phase 2)
Stomach Neoplasms (Phase 4)
Survival (Phase 4)
Tay-Sachs Disease (Phase 1/Phase 2)
Testicular Neoplasms (Phase 3)
Thrombocytopenia (Phase 2)
Thymoma (Phase 4)
Toxoplasmosis (Phase 4)
Toxoplasmosis, Cerebral (Phase 2)
Triple Negative Breast Neoplasms (Phase 1/Phase 2)
Urethral Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 2/Phase 3)
Uterine Cervical Neoplasms (Phase 3)
Uterine Neoplasms (Phase 2)
Uveitis (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
